In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD). A ...
A retrospective analysis of Canadian cases finds clinicians turn to a variety of therapies for chronic graft-vs-host disease (GVHD) if corticosteroids fail. A new review of chronic graft-vs-host ...
Graft-versus-host disease (GVHD) is a common side effect in people who receive cells from a donor (allogeneic transplant). It occurs when the transplanted cells recognize the recipient’s tissues as ...
Hosted on MSN
What To Know About Graft vs. Host Disease (GVHD)
Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which can treat some cancers. GVHD happens when ...
In preparation for a potential “paradigm shift” in the management of graft-versus-host disease (GVHD), the US Food and Drug Administration (FDA) is seeking comment on draft guidance for developing ...
Picture this: you’re surviving cancer, chemotherapy, radiation, immunosuppression, and a blood stem cell transplant, and you haven’t left the hospital in weeks. Yet, somehow, you have what feels and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results